Immunovant (NASDAQ:IMVT) advances autoimmune research as nasdaq today reflects activity across clinical-stage biotech ...
A few 2025 trials pointed in the same direction: toward treatments built to modify disease biology and better ways to measure ...
The team conducted an extensive evaluation to clarify whether the presence of TPO antibodies contributes to cardiovascular ...
Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive ...
best colostrum supplement of 2026, combining clean sourcing, advanced formulation, and science-backed wellness benefits.
The anti-CD40 antibody tegoprubart offers a tacrolimus-free immunosuppression option for preventing islet transplant ...
The Food and Drug Administration has approved Yartemlea ® (narsoplimab-wuug) for the treatment of adult and pediatric patients aged 2 years and older with hematopoietic stem cell transplant ...
Advances delivered what may feel like medical miracles, including the first bladder transplant, a lifesaving personalized ...
MedPage Today on MSN
First Drug for Deadly Transplant Complication Gets FDA's Blessing
The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...
It’s hard to keep up with all the discoveries made around the world every year in science, but harder still to sort the hype ...
Chronic circadian disruption — such as night-shift work, irregular schedules, or frequent jet lag — accelerates the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback